- Home
- EVOK vs PRFX Comparison
EVOK vs PRFX Comparison
Compare EVOK & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- PRFX
- Stock Information
- Founded
- EVOK 2007
- PRFX 2007
- Country
- EVOK United States
- PRFX Israel
- Employees
- EVOK N/A
- PRFX N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- PRFX Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- PRFX Health Care
- Exchange
- EVOK Nasdaq
- PRFX Nasdaq
- Market Cap
- EVOK 4.2M
- PRFX 3.8M
- IPO Year
- EVOK 2013
- PRFX 2020
- Fundamental
- Price
- EVOK $3.22
- PRFX $1.91
- Analyst Decision
- EVOK
- PRFX Hold
- Analyst Count
- EVOK 0
- PRFX 1
- Target Price
- EVOK N/A
- PRFX N/A
- AVG Volume (30 Days)
- EVOK 13.8K
- PRFX 365.5K
- Earning Date
- EVOK 05-13-2025
- PRFX 05-23-2025
- Dividend Yield
- EVOK N/A
- PRFX N/A
- EPS Growth
- EVOK N/A
- PRFX N/A
- EPS
- EVOK N/A
- PRFX N/A
- Revenue
- EVOK $11,594,083.00
- PRFX N/A
- Revenue This Year
- EVOK $58.84
- PRFX N/A
- Revenue Next Year
- EVOK $58.11
- PRFX N/A
- P/E Ratio
- EVOK N/A
- PRFX N/A
- Revenue Growth
- EVOK 89.89
- PRFX N/A
- 52 Week Low
- EVOK $1.94
- PRFX $0.43
- 52 Week High
- EVOK $12.32
- PRFX $16.63
- Technical
- Relative Strength Index (RSI)
- EVOK 62.15
- PRFX 37.78
- Support Level
- EVOK $3.00
- PRFX $2.22
- Resistance Level
- EVOK $3.29
- PRFX $2.04
- Average True Range (ATR)
- EVOK 0.21
- PRFX 0.12
- MACD
- EVOK 0.05
- PRFX -0.02
- Stochastic Oscillator
- EVOK 80.82
- PRFX 10.00
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.